Abstract:Focal adhesion lcinase (FAK) is considered as an attractive target for oncology. A series of F-18 labeled 5bromo-N-2-(4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl)-N-4-(4-methoxyphenyl)pyrimidine2,4-diamine derivatives were prepared and evaluated as the FAK targeted radiotracers for the early diagnoses of tumor. For the study of the FAK targeted drug molecules, this was the first attempt to develop the tumor diagnostic imaging agents on the radiopharmaceutical level. They inhibited the activity of FAK with IC50 in the range of 91.4-425.7 nM, and among which the result of the [F-19]2 was relatively good and had a modest IC50 of 91.4 nM. The [F-19]2 was also profiled in vitro against some other kinds of cancer related kinases (including two kinds of non-receptor tyrosine kinase: PYK2 and JAK2, and three kinds of receptor tyrosine kinase: IGF-1R, EGFR and PDGFR(3). It displayed 25.2 folds selectivity against PYK2, 35.1 folds selectivity against EGFR, and more than 100 folds selectivity against IGF-1R, JAK2 and PDGFRO. For the biodistribution in 5180 bearing mice, the corresponding [F-18]2 were also relatively good, with modest tumor uptake of 5.47 +/- 0.19 and 5.80 +/- 0.06 %ID/g at 15 and 30 min post-injection, respectively. Furthermore, its tumor/muscle, tumor/bone and tumor/blood ratio at 15 min post-injection were 3.16, 2.53 and 4.52, respectively. And its tumor/muscle, tumor/bone and tumor/blood ratio at 30 min post injection were 3.14, 2.76 and 4.43, respectively. In addition, coronal micro-PET/CT images of a mouse bearing 5180 tumor clearly confirmed that [F-18]2 could be accumulated in tumor, especially at 30 min post-injection. Besides, for the jI8F12, both the biodistribution data and the micro-PET/CT imaging study showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC50 value of 1.5 nM) at 1 h before the injection of radiotracer. In combination with the above kinase profiling assay, it could be indicated that the uptake of [F-18]2 in tumor of the mouse model was due to FAK expression, and that [F-18]2 might be a kind of selectively FAK targeted tumor imaging agents. What's more, the results of the MD (molecular dynamics) simulations were in agreement with the changing trends of the interaction between the different F-19 standards and the FAK (expressed as the in vitro inhibitory abilities of enzymatic activities of FAK in this article), which was also in agreement with and had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios. (C) 2017 Elsevier Masson SAS. All rights reserved.

Design, Synthesis, Biological Evaluation and Molecular Docking of Novel F-18-Labeled Focal Adhesion Kinase Inhibitors as Potential Tumor Radiotracers

Preparation, in Vitro and in Vivo Evaluation, and Molecular Dynamics (MD) Simulation Studies of Novel F-18 Labeled Tumor Imaging Agents Targeting Focal Adhesion Kinase (FAK)

Design, Synthesis, and Biological Evaluation of 4-Arylamino Pyrimidine Derivatives As FAK Inhibitors and Tumor Radiotracers.

Design, Synthesis, Biological Evaluation, and Molecular Docking of 2,4-Diaminopyrimidine Derivatives Targeting Focal Adhesion Kinase As Tumor Radiotracers.

Synthesis, Biological Evaluation, and Molecular Dynamics (MD) Simulation Studies of Three Novel F-18 Labeled and Focal Adhesion Kinase (FAK) Targeted 5-Bromo Pyrimidines As Radiotracers for Tumor.

Design, Synthesis, and Biological Evaluation of F-18-labelled 2, 4-Diaminopyrimidine-type FAK-targeted Inhibitors As Potential Tumour Imaging Agents

High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Synthesis and Evaluation of 99Mtc-Labeled FAP Inhibitors with Different Linkers for Imaging of Fibroblast Activation Proteins in Tumors

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

Synthesis and Preclinical Evaluation of Novel 18F-Labeled Fibroblast Activation Protein Tracers for Positron Emission Tomography Imaging of Cancer-Associated Fibroblasts.

Synthesis and Evaluation of Novel F-18-Labeled Pyrimidine Derivatives: Potential Fak Inhibitors and Pet Imaging Agents for Cancer Detection

Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3

Rational modifications on N -(4-quinolinoyl)-Gly-2-cyanopyrrolidine to develop fibroblast activation protein-targeted radioligands with improved affinity and tumor uptake

Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein.

Preparation and Bioevaluation of <SUP>99m</SUP>Tc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein

Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation

Synthesis and Evaluation of Novel F-18 Labeled Fluoroarylvaline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Rational Design and Pharmacomodulation of 18F-Labeled Biotin/FAPI-Conjugated Heterodimers

Rational Design and Pharmacomodulation of 18F-Labeled Biotin/FAPI-Conjugated Heterodimers.